By analyzing existing basic indicators between IsoRay and ElectroCore, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in ElectroCore with a short position in IsoRay. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. IsoRay has an asset utilization ratio of 51.49 percent. This connotes that the company is making $0.51 for each dollar of assets. An increasing asset utilization means that IsoRay Inc is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as IsoRay or Lifevantage is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is IsoRay's Liquidity
IsoRay
financial leverage refers to using borrowed capital as a funding source to finance IsoRay Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. IsoRay financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to IsoRay's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of IsoRay's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between IsoRay's total debt and its cash.
Correlation Between IsoRay and Lifevantage
In general, Delisted Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding IsoRay together with similar or unrelated positions with a negative correlation. For example, you can also add Lifevantage to your portfolio. If Lifevantage is not perfectly correlated to IsoRay it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When IsoRay, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both IsoRay and Lifevantage in your portfolio? Please note if you are using this as a pair-trade strategy between IsoRay and Lifevantage, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between ISR and LFVN for more information.
Another Deeper Perspective
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Now, let's check IsoRay revenue. Based on the latest financial disclosure, IsoRay Inc reported 9.32
M of revenue. This is 99.88% lower than that of the Healthcare sector and 99.49% lower than that of the
Medical Instruments & Supplies industry. The revenue for all United States stocks is 99.9% higher than that of the company. As for ElectroCore we see revenue of 2.84
M, which is 99.85% lower than that of the Medical Instruments & Supplies
| ISR | 9.32 Million | 0.5 |
| Sector | 1.84 Billion | 99.34 |
| ECOR | 2.84 Million | 0.15 |
Another 3 percent spike for IsoRay
Latest total risk alpha indicator falls down to -0.42. Possible price gain? As of the 16th of September 2020, IsoRay retains the
risk adjusted performance of
(0.0336), and Market Risk Adjusted Performance of 0.8485. IsoRay
technical analysis makes it possible for you to employ
historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to analyze nineteen
technical drivers for IsoRay Inc, which can be compared to its competitors. Please check out
IsoRay Inc standard deviation,
value at risk, as well as the
relationship between the Value At Risk and
kurtosis to decide if IsoRay is priced fairly, providing market reflects its last-minute price of 0.68 per share. As
IsoRay Inc is a penny stock we also advise to confirm its
total risk alpha numbers.
Our Takeaway on IsoRay Investment
When is the right time to buy or sell IsoRay Inc? Buying stocks such as IsoRay isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without
sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. The inconsistency in the assessment between current IsoRay valuation and our trade advice on IsoRay is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to IsoRay.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of IsoRay Inc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
